ERJ Express. Published on January 30, 2006 as doi: 10.1183/09031936.06.00087905

Alveolar nitric oxide *versus* measures of peripheral airway dysfunction in severe asthma

Ilonka H. van Veen, Peter J. Sterk, Robert Schot, Stefanie A. Gauw, Klaus F. Rabe and Elisabeth H. Bel

Dept. of Pulmonology
Leiden University Medical Center
The Netherlands

Corresponding author:
H.P.A.A. van Veen
Dept. of Pulmonology C3P-18
Leiden University Medical Center
Albinusdreef 2
2333 ZA, Leiden
The Netherlands
Tel: 00-31-71-5262950
Fax: 00-31-71-5266927
e-mail: h.p.a.a.van_veen@lumc.nl

Abstract

Alveolar nitric oxide (NO) is a measure of peripheral airway inflammation in asthma, potentially associated with disease severity. The relationship between alveolar NO and physiological tests of peripheral airway (dys)function has not been investigated. We hypothesised that peripheral airway inflammation and dysfunction are interrelated and associated with asthma severity.

Alveolar NO was compared between 17 patients with mild-to-moderate and 14 patients with severe asthma and related to total lung capacity (TLC), residual volume (RV/TLC), thoracic gas volume (FRC), slope of the single breath nitrogen washout curve (dN_2), closing capacity (CC/TLC) and fall in forced vital capacity during methacholine challenge (ΔFVC_{pc20}). In patients with severe asthma strong correlations were found between alveolar NO and RV/TLC%pred, FRC%pred, dN_2, and CC/TLC. Patients with oral steroid-dependent asthma had higher alveolar NO levels (2.7 ppb) compared to the other patients with severe (0.6 ppb) and mild-to-moderate asthma (0.3 ppb). We conclude that alveolar NO is closely related to parameters of peripheral airway dysfunction in patients with severe asthma, and that oral steroid-dependent asthmatics have more peripheral airway disease than non-steroid-dependent asthmatics. This suggests that patients on chronic oral steroid treatment have more extensive disease and require additional anti-inflammatory treatment to better target the peripheral airways.

Introduction

The need for understanding refractory asthma becomes increasingly important since milder forms of the disease can now be well treated(1). Little is known about the reason why some patients exhibit unstable disease despite maximum therapy with inhaled or even oral steroids. One of the proposed mechanisms is the presence of inflammation in the peripheral airways which seems to be an important feature of patients with asthma, in particular of those with severe disease(2-6). Inflammation of the distal lung in asthma has been demonstrated in post mortem tissue in patients who died from an asthmatic attack(2;6), in resected lung tissue(3) and in transbronchial biopsies(4;5) and has been suggested to contribute to instability of the disease(5;7), therapy resistance(8) and excessive airway narrowing(9).

Recent studies have shown that alveolar nitric oxide (NO) is a potentially useful measurement for investigating the role of peripheral airway inflammation in asthma. Alveolar NO has been related to bronchoalveolar lavage eosinophil cathionic protein (ECP) levels in children(10) and to bronchoalveolar lavage eosinophil counts in adults(11). However, the relationship between alveolar nitric oxide as a measure of peripheral airway inflammation and physiologic tests of peripheral airway function has never been investigated.

Over the years, several physiological tests have been proposed to estimate the degree of peripheral airway function(7;9;12-15). A few studies have investigated the relationship between some of these tests and pathological evidence of peripheral airway inflammation. The slope of the nitrogen single breath washout test appeared to be related to the degree of small airway inflammation in lung tissue from smokers in one study(12), whilst another study showed that thoracic gas volume (FRC) and total lung capacity (TLC) were related to the number of eosinophils in transbronchial biopsies from patients with severe asthma(14).

In the present study we hypothesized that the degree of peripheral airway inflammation and dysfunction are interrelated and positively associated with asthma severity. Therefore, we compared alveolar NO between patients with mild-to-moderate and severe asthma, and assessed the relationship between alveolar NO and six different physiological tests proposed to reflect peripheral airway function: total lung capacity (TLC), residual volume (RV/TLC), thoracic gas volume (FRC), the slope of the nitrogen washout test (dN_2), closing capacity (CC/TLC), and the fall in forced vital capacity during methacholine challenge (ΔFVC_{pc20}).

Methods

Subjects

Seventeen patients with mild-to-moderate asthma and 14 with severe asthma, according to previously published criteria(16), were recruited. All had a pulmonologist diagnosis of asthma and documented reversible airway obstruction(16). All patients were on inhaled steroid treatment. Patients with mild-to-moderate asthma were using ≤ 800 μg beclometasone/day (or equivalent) with beta-agonists prn. Patients with severe asthma were all using high doses of inhaled corticosteroids (≥1600 μg beclometasone/day, or ≥ 800 μg in case of chronic oral steroid use) plus long-acting beta-agonists, and occasionally additional leukotriene-antagonists (n=5). They had at least one exacerbation in the previous year requiring steroid treatment and/or were on chronic oral steroids. Current smokers and patients with a smoking history of more than 5 pack years were excluded from participation. The patients visited the lung function laboratory on 3 different days within one month. At day 1 alveolar NO measurements were performed before spirometry. Methacholine provocation test was performed on the second day. At day 3 lung volume measurements and the single breath nitrogen washout test were performed. The study was approved by the Ethics Committee of the Leiden University Medical Centre and all patients gave written informed consent.

Spirometry

FEV_1 and IVC before and after bronchodilation (inhalation of 400 μg salbutamol) were measured. Reversibility was expressed as postbronchodilator FEV_1 – prebronchodilator FEV_1 / FEV_1 predicted. Predicted values were obtained from Quanjer and co-workers and used for analysis(17).

Lung volumes

Lung volumes were measured (TLC, RV, FRC) pre-bronchodilation using body plethysmography according to standard methods(17). Predicted values were obtained from Quanjer and co-workers(17).

Methacholine provocation test; assessment of ΔFVC_{pc20}

Methacholine challenge testing was performed using a standardized tidal breathing method (18) modified according to Gibbons(9). Patients received doubling doses of methacholine starting with a dose of 0.03 mg/ml. After each dose FEV_1 and FVC were measured until FEV_1 dropped ≥ 20% compared to baseline (PC_{20}). The percentage fall in FVC at the PC_{20} concentration of methacholine (ΔFVC_{pc20}) was then calculated using log-linear interpolation.

Single breath Nitrogen washout test

Nitrogen single breath washout tests were performed in order to assess ventilation inhomogeneity. The slope of the nitrogen alveolar plateau (dN_2), closing volume and closing capacity were calculated as previously described(7).

Exhaled NO and calculation of alveolar NO levels

Exhaled NO (FeNO) was measured according to criteria of the American Thoracic Society(19) at three different flow rates: 100, 175 and 370 ml/sec, with a chemoluminescence analyser (Sievers, NOA 270B), mouth pressure 8-10 cmH_2O(20). At each flow rate at least three technically adequate measurements were performed. FeNO was measured at a plateau between 5 and 8 seconds after reaching the correct exhalation flow rate or, in case of insufficient exhalation time, during a plateau phase of at least three seconds(19). The average value was then taken for analysis. Measurements were excluded if an adequate NO plateau could not be reached, or if NO levels were below the detection limit. The contributions of the

bronchi (bronchial NO flux) and the alveoli (alveolar NO concentration) to exhaled NO were derived from regression analysis, with NO output as dependent and exhalation flow rate as independent factor(20). The slope and intercept of the regression line are approximates of alveolar NO concentration and bronchial NO flux, respectively.

Analysis

Unpaired Student's *t*-test, non-parametric tests (Mann Whitney, Kruskal Wallis) and chi-square analysis were used to analyse differences between groups. Spearman correlation coefficients were used to assess relationships between different parameters. All analyses were performed using the Statistical Package of the Social Sciences (SPSS-12.0). P-values less than 0.05 were considered statistically significant.

Results

1. Patient Characteristics

See table 1. Patients with mild-to-moderate and severe asthma did not differ with respect to age and gender. Patients with severe asthma were using higher doses inhaled steroids as defined in the inclusion criteria, 43% of them were using oral corticosteroids (median (range) dose: 7.5 (2.5-15) mg.). Post-bronchodilator FEV_1 was higher in the patients with mild-to-moderate asthma and these patients had more reversibility in FEV_1.

2. Alveolar NO measurements

Adequate alveolar NO measurements could be performed in 16 patients with mild-to-moderate and 10 patients with severe asthma. One patient with mild and 4 patients with severe asthma were excluded because of the lack of an adequate NO plateau or because of a NO concentration below the detection limit at one or more flow rates (this was the case in 1 patient with mild and 2 with severe asthma). The linearity of the relationship between NO output and exhalation flow rate was satisfactory (mean R = 0.82). In 5 patients with mild-to-moderate asthma and 2 with severe asthma a negative association between NO-output and exhalation flow rate was found, resulting in negative alveolar NO concentrations.

3. Comparison between mild-to-moderate and severe asthma

a. Alveolar NO

   Alveolar NO was not different between the patients with severe and mild-to-moderate asthma (Table 2, Figure 1). However, the subgroup of oral steroid-

dependent patients had significantly higher alveolar NO levels (median (range) 2.7 (2.0-9.6) ppb) than the non-steroid-dependent patients with severe asthma (0.6 (-2.8-8.3) ppb, p=0.05) or those with mild-to-moderate asthma (0.3 (-1.4-3.9) ppb, p=0.01) (Table 3). Exhaled NO at 100 ml/sec and bronchial NO flux were similar in patients with mild-to-moderate and (steroid-dependent) severe asthma (p=0.93 and 0.82 resp.)

b. Functional parameters

In the total group of patients with severe asthma only dN_2 and ΔFVC_{pc20} were higher than in the patients with mild-to-moderate asthma (Table 2, Figure 2). Surprisingly, TLC%pred was higher in the patients with mild-to-moderate asthma as compared to severe asthma.

In the subgroup of patients with severe steroid-dependent asthma dN_2, RV/TLC%pred. and CC/TLC were significantly higher than in the other patients with severe asthma (Table 3).

4. Relationship between alveolar NO and functional parameters

In the total group of patients with mild-to-moderate and severe asthma there were no correlations between alveolar NO and functional parameters except for dN_2 (r=0.45, p=0.02, Figure 3). However, within the group of patients with severe asthma, alveolar NO correlated strongly and positively with all functional parameters of airway dysfunction: FRC%pred. (ρ=0.84, p=0.002), RV/TLC%pred (ρ=0.83, p=0.003), dN_2 (ρ=0.72; p=0.02), and CC/TLC (ρ=0.86; p=0.002), except for TLC%pred (p=0.26) and ΔFVC_{pc20} (p=0.82) (Figure 4). In patients with mild-to-moderate asthma there was no correlation between alveolar NO and any of the functional parameters.

Table 1. Patient characteristics in mild-to moderate and severe asthma.

	Mild-to-moderate asthma (n=17)	Severe asthma (n=14)	p-value
Age (yrs)	35.7 (10.9)	43.4 (16.6)	0.13
Female sex (%)	59	57	0.93
Inhaled steroid (μg)	445 (185)	1155 (455)	0.000
Oral steroid (n)	0	6	0.004
$PbFEV_1$ (%pred)*	102 (80-120)	89 (40-109)	0.04
Reversibility (%)*	11.0 (1-29.2)	7.2 (0-22.5)	0.003

Values in mean (sd), * median (range), Pb=post-bronchodilator

Table 2. Outcome parameters in mild-to moderate and severe asthma.

	Mild-to-moderate asthma (n=17)	Severe asthma (n=14)	p-value
Alv. NO (ppb)*	0.3 (-1.4- 3.9)	1.9 (-2.8-9.6)	0.11
Br. NO (nl/s)*	1.9 (0.8-4.3)	2.1 (0.1-5.8)	0.94
FRC (%pred)	118.8 (22.8)	101.8 (25.2)	0.06
TLC (%pred)	104.0 (11.6)	94.9 (8.0)	0.02
RV/TLC (%pred)	105.5 (25.9)	113.4 (18.2)	0.35
dN_2 (%/L)*	0.8 (0.3-2.1)	1.6 (0.5-9.1)	0.02
CC/TLC (L)	39.7 (6.3)	46.8 (12.0)	0.06
ΔFVC_{pc20} (%)*	10.8 (4.0-19.1)	13.5 (11.4-21.8)	0.03

Values in mean (sd), * median (range). Alveolar NO and Bronchial NO were measured in 16 patients with mild-to-moderate and 10 patients with severe asthma.

Table 3. Comparison of steroid dependent and non-steroid-dependent severe asthma.

	Severe Asthma		
	oral steroids (n=6)	no oral steroids (n=8)	p-value
Alv. NO (ppb)	2.7 (2.0-9.6)	0.6 (-2.8-8.3)	0.05
Br. NO (nl/s)	1.8 (0.1-2.4)	2.1 (0.6-5.9)	0.67
$FeNO_{100}$ (ppb)	20.7 (5.4-33.4)	19.8 (6.6-57.8)	0.67
FRC (%pred)	113.5 (89-141)	84.5 (61-131)	0.07
TLC (%pred)	93.5 (90-104)	96 (81-111)	1.0
RV/TLC (%pred)	123.5 (113-162)	103.5 (86-117)	0.004
dN_2 (%/L)	3.2 (1.1-9.1)	1.0 (0.5-2.2)	0.02
CC/TLC (%)	53.8 (44-70)	40.3 (29-53)	0.01
ΔFVC_{pc20} (%)	12.9 (11.4-14.2)	14.6 (11.7-21.8)	0.26

Values in median (range). Alveolar NO and Bronchial NO were measured in 4 patients with and 6 patients without oral steroids.

Discussion

This study shows that alveolar NO is closely related to parameters of peripheral airway dysfunction in patients with severe asthma, but not in patients with mild-to-moderate asthma. Within the group of patients with severe asthma, those patients on continuous oral corticosteroid treatment had more peripheral airway inflammation and dysfunction than patients with severe asthma on inhaled corticosteroids alone, and patients with mild-to-moderate asthma. This suggests that peripheral airway inflammation is not related to asthma severity per se, although it seems to be an important characteristic of patients with steroid-dependent asthma.

In this study alveolar NO levels could be adequately measured in the majority of adults with asthma of varying severity, including severe asthma. As compared to other investigators who measured alveolar NO in adults with mild-to-moderate persistent asthma(21), severe asthma(11) and in children with mild(22), and refractory asthma(10), we obtained alveolar NO levels in a lower range (3-4 fold lower). This could be due to differences between patient characteristics, and/or differences in the technical aspects of the measurements, such as the use of higher flow rates to calculate alveolar NO in our study. The alveolar NO levels in our study were comparable to those of Lehtimaki, who used the same flow rates and was the first to measure alveolar NO levels in patients with asthma (23;24)

The comparison of alveolar NO levels between patients with mild-to-moderate asthma and severe asthma did not reveal a significant difference after initial analysis, which was surprising. In studies by other groups higher levels of alveolar NO were found in symptomatic children versus asymptomatic children with asthma(22), in patients with nocturnal asthma as compared to non-nocturnal asthma(23) and in

patients with severe versus mild-to-moderate asthma(11). The explanation for a lack of significant difference in alveolar NO levels between patients with mild-to-moderate and severe asthma in our study could be the large variability of alveolar NO-levels amongst the patients with severe asthma. Apparently, these patients are heterogeneous with respect to their degree of peripheral airway inflammation. When considering the subgroup of patients with oral corticosteroid dependency much higher alveolar NO levels were observed as compared to patients on inhaled corticosteroids alone. The same holds for the parameters of peripheral airway dysfunction. This is remarkable because one could expect that systemic treatment in these patients would reduce the amount of peripheral airway inflammation and dysfunction. Apparently, there is extensive peripheral airway disease in these patients, which is not fully controlled by such a high level of anti-inflammatory treatment. The heterogeneity of patients with severe asthma is thus an important factor to be taken into account when studying disease mechanisms in these patients.

Alveolar NO and parameters of peripheral airway dysfunction showed strong and positive correlations in the patients with severe asthma, but not in patients with mild asthma or in the group as a whole (except for dN_2). Probably, most of these parameters are not sensitive enough to detect small changes in patients with milder disease of the peripheral airways. The strong association between alveolar NO and almost all parameters of airway dysfunction suggests that these two entities coexist and are possibly causally related. This fits in with the recently observed relationship between FeNO and dN_2 in patients with mild asthma(25) and in smokers(26). Additional anti-inflammatory treatment specifically targeting the peripheral airways might improve peripheral airway function and thereby overall lung function in patients with severe asthma.

ΔFVC_{pc20} was not related to alveolar NO, although there was a significant difference in this parameter between mild-moderate and severe asthma. ΔFVC_{pc20} is a measurement that is performed after stimulation of the bronchi with the bronchoconstrictor agent methacholine. It is assumed that the more FVC decreases during bronchoconstriction the more closure of peripheral airways has occurred. The major difference with the other tests of peripheral airway dysfunction is that ΔFVC_{pc20} is measured in constricted airways, thereby mimicking an acute asthma attack. The discrepancy between ΔFVC_{pc20} and the other tests suggest that airway dysfunction at rest does not predict the dynamics of peripheral airway dysfunction during acute bronchoconstriction. This is compatible with mathematical models of airway function(27). Thus, peripheral airway disease at rest and peripheral airway dysfunction during bronchoconstriction are two distinct conditions that do not necessarily coexist within the same subject, and may be reflected by different tests of peripheral airways disease.

The present study may have some limitations. First, the power of the study might not have been enough to detect statistical significant differences between the groups of patients with mild-to-moderate and severe asthma. In retrospect, based on the present study data, the power was enough to detect a difference in mean alveolar NO of 5.0 ppb. In order to detect a difference of 2 ppb, 57 patients would have been needed in each group. Secondly, the calculation of alveolar NO is based on a mathematical two-compartment model, which has its limitations. In seven patients negative alveolar NO values were calculated, while the measurements were technically adequately performed. The choice of expiratory flows rates of 100, 175 and 370 ml/sec hampered an adequate estimation of the NO concentration – expiratory flow rate curve in these patients. To improve this we would have needed

measurements at extra flow rates, especially in the higher range, however this is difficult to achieve in patients with flow limitation. This indicates that the model used (with these expiratory flows) was not completely sufficient for all patients. Until now, however, there are no better tests for the assessment of peripheral airway inflammation in patients with asthma except for invasive tests such as transbronchial biopsies.

The results of this study have implications for the assessment and treatment of patients with severe asthma. Similar to the fractional concentration of NO in exhaled air, alveolar NO could be successfully used to guide therapy in asthma(28;29). This study shows that patients with similar fractional levels of exhaled NO can have different alveolar NO levels. Thus, alveolar NO provides additive information for the clinician. The elevated levels of alveolar NO in patients already on continuous oral corticosteroids, suggest that the inflammatory process in the peripheral airways is extensive and still relatively undertreated despite the administration of systemic treatment. Measurement of alveolar NO levels might therefore be used in clinical practice to adjust anti-inflammatory treatment, for example by the addition of fine-particle inhaled corticosteroids or novel systemic anti-inflammatory therapies. In this way it might be possible to improve disease severity, avoid excessive airway narrowing and prevent a poor prognosis.

In conclusion, alveolar NO is an easy to perform, non-invasive test to estimate the degree of peripheral airway inflammation. It provides important information on peripheral airway disease and can be used in addition to functional tests such as TLC, RV/TLC, FRC, dN_2, CC/TLC or ΔFVC_{pc20}. Patients with severe asthma are heterogeneous with respect to the degree of peripheral airway disease. Those patients who are dependent on oral corticosteroids seem to have the most prominent

signs of peripheral airway inflammation and dysfunction. This suggests that these patients might require additional or alternative anti-inflammatory treatment to better target the peripheral airways. Alveolar NO might become an important new tool for the clinician to detect insufficiencies of asthma treatment, to tailor asthma therapies in individual patients, and to improve asthma control.

References

(1) Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162(6):2341-2351.

(2) Carroll N, Cooke C, James A. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. Eur Respir J 1997; 10:292-300.

(3) Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997; 100:44-51.

(4) Hauber HP, Gotfried M, Newman K, Danda R, Servi RJ, Christodoulopoulos P et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003 Jul ;112 (1):58 -63.

(5) Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154:1505-1510.

(6) Mauad T, Silva LF, Santos MA, Grinberg L, Bernardi FD, Martins MA et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170(8):857-862.

(7) in 't Veen, Beekman AJ, Bel EH, Sterk PJ. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes. Am J Respir Crit Care Med 2000 Jun ;161 (6):1902 -6.

(8) ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170(6):601-605.

(9) Gibbons WJ, Sharma A, Lougheed D, Macklem PT. Detection of excessive bronchoconstriction in asthma. Am J Respir Crit Care Med 1996; 153:582-589.

(10) Mahut B, Delclaux C, Tillie-Leblond I, Gosset P, Delacourt C, Zerah-Lancner F et al. Both inflammation and remodeling influence nitric oxide output in children with refractory asthma. J Allergy Clin Immunol 2004; 113(2):252-256.

(11) Berry M, Hargadon B, Morgan A, Shelley M, Richter J, Shaw D et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005; 25(6):986-991.

(12) Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978; 298:1277-1281.

(13) Pliss LB, Ingenito EP, Ingram RH, Jr. Responsiveness, inflammation, and effects of deep breaths on obstruction in mild asthma. J Appl Physiol 1989; 66(5):2298-2304.

(14) Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD, Kraft M. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113(6):1046-1050.

(15) Woolcock AJ, Vincent NJ, Macklem PT. Frequency dependence of compliance as a test for obstruction in the small airways. J Clin Invest 1969; 48:1097-1106.

(16) The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003 Sep ;22 (3):470 -7.

(17) Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung

Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.

(18) Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:53-83.

(19) Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999; 160:2104-2117.

(20) Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998; 85:653-666.

(21) Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM et al. Alveolar and Airway Sites of Nitric Oxide Inflammation in Treated Asthmatics. Am J Respir Crit Care Med 2004.

(22) Mahut B, Delacourt C, Zerah-Lancner F, de Blic J, Harf A, Delclaux C. Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. Chest 2004; 125(3):1012-1018.

(23) Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J 2002 Oct ;20 (4):841 -5.

(24) Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Peripheral inflammation in patients with asthmatic symptoms but normal lung function. J Asthma 2005; 42(7):605-609.

(25) Battaglia S, den Hertog H, Timmers MC, Lazeroms SP, Vignola AM, Rabe KF et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60(8):639-644.

(26) Olin AC, Andelid K, Vikgren J, Rosengren A, Larsson S, Bake B et al. Single breath N(2)-test and exhaled nitric oxide in men. Respir Med 2005.

(27) Wang L, McParland BE, Pare PD. The functional consequences of structural changes in the airways: implications for airway hyperresponsiveness in asthma. Chest 2003; 123(3 Suppl):356S-362S.

(28) Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172(7):831-836.

(29) Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352(21):2163-2173.


p= 0.02
10
1
0.1
dN_2 (%/L)
Mild-to-moderate
Severe


p=0.11
9.5
7.0
4.5
2.0
-0.5
-3.0
Alveolar NO (ppb)
Mild-to-moderate
Severe


10,00
1,00
dN2 (%/L)
rho=0.45, p=0.02
-1,00
-0,10
1,00
10,00
alveolar NO (ppb)


140
120
100
80
60
FRC %pred
rho=0.84, p=0.002
-1,00
-0,10
1,00
10,00
alveolar NO (ppb)


150
100
RV/TLC %pred
rho=0.83, p=0.003
-1,00
-0,10
1,00
10,00
alveolar NO (ppb)